OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Cohen on the Use of Chemoimmunotherapy in CLL

November 16th 2019

Jonathon B. Cohen, MD, MS, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Sartor on the VISION Trial in mCRPC

November 16th 2019

A. Oliver Sartor, MD, discusses the phase III VISION trial in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.

Dr. Kim on Treatment for BRAF-Mutant Colon Cancer

November 16th 2019

Richard Kim, MD, discusses treatment options for BRAF-mutant colon cancer.

Dr. Hidalgo Medina on Neoadjuvant Therapy in Pancreatic Cancer

November 16th 2019

Manuel Hidalgo Medina, MD, PhD, discusses the emergence of neoadjuvant chemotherapy and radiation in pancreatic cancer.

Dr. Rule on the FDA Approval of Zanubrutinib in MCL

November 15th 2019

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the FDA approval of zanubrutinib (Brukinsa) in mantle cell lymphoma (MCL).

Dr. Vidal on Potential of [Fam-] Trastuzumab Deruxtecan in HER2+ Breast Cancer

November 15th 2019

Gregory Vidal, MD, PhD, discusses the potential of [fam-] trastuzumab deruxtecan in HER2-positive breast cancer.

Dr. Levy on Molecular Drivers in NSCLC

November 15th 2019

Benjamin P. Levy, MD, discusses the identification of molecular drivers in non–small cell lung cancer.

Dr. Bestvina on the KEYNOTE-407 Trial in Squamous NSCLC

November 15th 2019

Christine Bestvina, MD, discusses the phase III KEYNOTE-407 trial in squamous non–small cell lung cancer.

Dr. Giralt on Evaluating MRD in Multiple Myeloma

November 15th 2019

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses methods of evaluating measurable residual disease (MRD) in multiple myeloma.

Dr. Leath on Agents Under Investigation in Cervical Cancer

November 15th 2019

Charles A. Leath III, MD, gynecologic oncologist at the University of Alabama at Birmingham, discusses agents under investigation in cervical cancer.

Dr. Somer on Hesitancy Regarding Biosimilar Use in Oncology

November 15th 2019

Bradley G. Somer, MD, associate professor, Department of Hematology and Medical Oncology, University of Tennessee Health Science Center, medical oncologist, senior partner, Executive Cancer Council, and head of strategic expansion/development, West Cancer Center Research Program, West Cancer Center, explains where the hesitancy regarding biosimilar use in oncology.

Dr. Schwartzberg on Increasing Competition With Biosimilars in Oncology

November 14th 2019

Lee S. Schwartzberg, MD, FACP, explains how biosimilars could lead to increased competition in oncology.

Dr. Coleman on Ongoing Research in Cervical Cancer

November 14th 2019

Robert L. Coleman, MD, FACOG, FACS, discusses ongoing research efforts in cervical cancer.

Dr. Long on Rationale for Nivolumab/Ipilimumab in Patients With Melanoma Who Have Brain Mets

November 14th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the rationale for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with melanoma who have brain metastases.

Dr. Fidler on RELAY Trial Results in EGFR+ NSCLC

November 14th 2019

Mary J. Fidler, MD, discusses the results of the phase III RELAY trial in treatment-naïve patients with EGFR-mutant non–small cell lung cancer.

Dr. Nooka on Treatment Options for Transplant-Eligible and -Ineligible Multiple Myeloma

November 14th 2019

Ajay K. Nooka, MD, MPH, FACP, discusses current options for transplant-eligible and -ineligible patients with multiple myeloma.

Dr. Vargas on Toxicity of SBRT Versus Standard Radiation in Prostate Cancer

November 13th 2019

Carlos E. Vargas, MD, discusses toxicities associated with stereotactic body radiation therapy compared with standard fractionated radiation therapy in prostate cancer.

Dr. Rule on the Future Treatment Paradigm in MCL

November 13th 2019

Simon Rule, MD, PhD, discusses what the treatment landscape of mantle cell lymphoma may look like in the next decade.

Dr. Kris on Search for Biomarkers in Advanced Squamous NSCLC

November 13th 2019

Mark G. Kris, MD, discusses the ongoing search for additional biomarkers in advanced squamous non–small cell lung cancer.

Dr. Borello on Treating Indolent Versus Aggressive Relapsed Multiple Myeloma

November 12th 2019

Ivan M. Borrello, MD, discusses treatment for patients with indolent versus aggressive relapsed multiple myeloma.